Trials / Completed
CompletedNCT02681978
Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease
Heart Rate Reduction by IVabradine for Improvement of ENDothELial Function in Patients With Coronary Artery Disease: the RIVENDEL Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Campus Bio-Medico University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effect of ivabradine on endothelial function in patients with coronary artery disease (CAD) after complete revascularization with percutaneous coronary angioplasty (PCI). At least 30 days after PCI, patients will be randomized to receive ivabradine 5 mg twice daily or to continue with standard medical therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivabradine | Ivabradine 5 mg twice daily |
| DRUG | Standard medical therapy | Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2016-02-15
- Last updated
- 2016-02-15
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02681978. Inclusion in this directory is not an endorsement.